Literature DB >> 25677735

Mutations in FLVCR2 associated with Fowler syndrome and survival beyond infancy.

M Kvarnung1,2, F Taylan1,3, D Nilsson1,2,3, M Albåge4, M Nordenskjöld1,2, B M Anderlid1,2, A Nordgren1,2, E Syk Lundberg1,2.   

Abstract

Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome (PVHH, OMIM 225790), also known as Fowler syndrome, is a rare autosomal recessive disorder, caused by mutations in FLVCR2. Hallmarks of the syndrome are glomerular vasculopathy in the central nervous system, severe hydrocephaly, hypokinesia and arthrogryphosis. The disorder is considered prenatally lethal. We report the first patients, a brother and a sister, with Fowler syndrome and survival beyond infancy. The patients present a phenotype of severe intellectual and neurologic disability with seizures, absence of functional movements, and no means of communication. Imaging of the brain showed calcifications, profound ventriculomegaly with only a thin edging of the cerebral cortex and hypoplastic cerebellum. Investigation with whole-exome sequencing (WES) revealed, in both patients, a homozygous pathogenic mutation in FLVCR2, c.1289C>T, compatible with a diagnosis of Fowler syndrome. The results highlight the power of combining WES with a thorough clinical examination in order to identify disease-causing mutations in patients whose clinical presentation differs from previously described cases. Specifically, the findings demonstrate that Fowler syndrome is a diagnosis to consider, not only prenatally but also in severely affected children with gross ventriculomegaly on brain imaging.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  FLVCR2; Fowler; hydranencephaly; intellectual disability; syndrome; whole-exome sequencing

Mesh:

Substances:

Year:  2015        PMID: 25677735     DOI: 10.1111/cge.12565

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

1.  Deficiency of MFSD7c results in microcephaly-associated vasculopathy in Fowler syndrome.

Authors:  Pazhanichamy Kalailingam; Kai Qi Wang; Xiu Ru Toh; Toan Q Nguyen; Madhuvanthi Chandrakanthan; Zafrul Hasan; Clair Habib; Aharon Schif; Francesca Clementina Radio; Bruno Dallapiccola; Karin Weiss; Long N Nguyen
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

Review 2.  Mitochondrial Targeting in Neurodegeneration: A Heme Perspective.

Authors:  Veronica Fiorito; Deborah Chiabrando; Emanuela Tolosano
Journal:  Pharmaceuticals (Basel)       Date:  2018-09-18

3.  Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome or Fowler syndrome: Report of a family and insight into the disease's mechanism.

Authors:  Francesca Clementina Radio; Lavinia Di Meglio; Emanuele Agolini; Emanuele Bellacchio; Martina Rinelli; Paolo Toscano; Renata Boldrini; Antonio Novelli; Aniello Di Meglio; Bruno Dallapiccola
Journal:  Mol Genet Genomic Med       Date:  2018-03-03       Impact factor: 2.183

Review 4.  Clinical Application of Genome and Exome Sequencing as a Diagnostic Tool for Pediatric Patients: a Scoping Review of the Literature.

Authors:  Hadley Stevens Smith; J Michael Swint; Seema R Lalani; Jose-Miguel Yamal; Marcia C de Oliveira Otto; Stephan Castellanos; Amy Taylor; Brendan H Lee; Heidi V Russell
Journal:  Genet Med       Date:  2018-05-14       Impact factor: 8.822

Review 5.  Targeting iron metabolism in drug discovery and delivery.

Authors:  Bart J Crielaard; Twan Lammers; Stefano Rivella
Journal:  Nat Rev Drug Discov       Date:  2017-02-03       Impact factor: 84.694

Review 6.  Unraveling the Role of Heme in Neurodegeneration.

Authors:  Deborah Chiabrando; Veronica Fiorito; Sara Petrillo; Emanuela Tolosano
Journal:  Front Neurosci       Date:  2018-10-09       Impact factor: 4.677

7.  Epilepsy syndromes, etiologies, and the use of next-generation sequencing in epilepsy presenting in the first 2 years of life: A population-based study.

Authors:  Tommy Stödberg; Torbjörn Tomson; Michela Barbaro; Henrik Stranneheim; Britt-Marie Anderlid; Sofia Carlsson; Per Åmark; Anna Wedell
Journal:  Epilepsia       Date:  2020-09-23       Impact factor: 5.864

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.